European Journal of Epidemiology

, Volume 24, Issue 4, pp 211–216 | Cite as

Rise in psychotropic drug prescribing in children and adolescents during 1992–2001: a population-based study in the UK

Pharmaco-Epidemiology

Abstract

Background The trend towards increased psychotropic drug prescribing in children and adolescents is well recognised in North America and continental Europe. However, it is unclear to what extent these studies are applicable to clinical practice in the United Kingdom (UK). This study was conducted to estimate the prevalence of psychotropic drug prescribing in children and adolescents aged <19 years in general practice in the UK from January 1992 to December 2001. Methods Data were obtained from the General Practice Research Database (GPRD). Annual age- and sex-specific prevalence of psychotropic drug prescribing was calculated. Results A total of 143,079 prescriptions were issued to 34,398 study subjects. Stimulant prescriptions rose significantly from 0.03 per 1,000 (95% confidence interval 0.02–0.04) in 1992 to 2.9 per 1,000 (2.52–3.32) in 2001; a 96-fold increase. Methylphenidate accounted for the majority of stimulant prescriptions; 2.4% (349/14,370) of stimulant prescriptions were prescribed to children aged <6 years. Increased prescribing was also noted for antidepressants (1.6-fold), hypnotics/anxiolytics (1.3-fold), antipsychotics (1.3-fold) and anticonvulsants (1.3-fold), whilst the prevalence of clonidine and lithium prescribing remained fairly stable throughout the study period. The use of antidepressant, hypnotic/anxiolytic and anticonvulsant increased with increasing age. A high proportion of boys received stimulants, whereas antidepressants and hypnotics/anxiolytics were more likely prescribed to girls. Conclusion There is an increased trend of psychotropic drug use in children and adolescents in the UK practice. Since most psychotropic drugs are not licensed for use in children at this time, research is needed to investigate the efficacy and long-term safety in this population.

Keywords

Psychotropic drug Children Adolescent Drug utilization Prevalence 

References

  1. 1.
    Zito JM, Safer DJ, DosReis S, Gardner JF, Soeken K, Boles M, et al. Rising prevalence of antidepressants among US youths. Pediatrics. 2002;109:721–7. doi:10.1542/peds.109.5.721.PubMedCrossRefGoogle Scholar
  2. 2.
    Zito JM, Safer DJ, DosReis S, Gardner JF, Magder L, Soeken K, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med. 2003;157:17–25.PubMedGoogle Scholar
  3. 3.
    Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA. 2000;283:1025–30. doi:10.1001/jama.283.8.1025.PubMedCrossRefGoogle Scholar
  4. 4.
    Hugtenburg JG, Heerdink ER, Egberts AC. Increased psychotropic drug consumption by children in the Netherlands during 1995–2001 is caused by increased use of methylphenidate by boys. Eur J Clin Pharmacol. 2004;60:377–9. doi:10.1007/s00228-004-0765-9.PubMedCrossRefGoogle Scholar
  5. 5.
    Schirm E, Tobi H, Zito JM, de Jong-van den Berg LT. Psychotropic medication in children: a study from the Netherlands. Pediatrics. 2001;108:E25. doi:10.1542/peds.108.2.e25.PubMedCrossRefGoogle Scholar
  6. 6.
    Rappley MD, Mullan PB, Alvarez FJ, Eneli IU, Wang J, Gardiner JC. Diagnosis of attention-deficit/hyperactivity disorder and use of psychotropic medication in very young children. Arch Pediatr Adolesc Med. 1999;153:1039–45.PubMedGoogle Scholar
  7. 7.
    Rappley MD, Eneli IU, Mullan PB, Alvarez FJ, Wang J, Luo Z, et al. Patterns of psychotropic medication use in very young children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr. 2002;23:23–30.PubMedGoogle Scholar
  8. 8.
    Guevara J, Lozano P, Wickizer T, Mell L, Gephart H. Psychotropic medication use in a population of children who have attention-deficit/hyperactivity disorder. Pediatrics. 2002;109:733–9. doi:10.1542/peds.109.5.733.PubMedCrossRefGoogle Scholar
  9. 9.
    The MTA Cooperative Group. Multimodal treatment study of children with ADHD A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1073–86. doi:10.1001/archpsyc.56.12.1073.CrossRefGoogle Scholar
  10. 10.
    Kollins S, Greenhill L, Swanson J, Wigal S, Abikoff H, McCracken J, et al. Rationale, design, and methods of the Preschool ADHD Treatment Study (PATS). J Am Acad Child Adolesc Psychiatry. 2006;45:1275–83. doi:10.1097/01.chi.0000235074.86919.dc.PubMedCrossRefGoogle Scholar
  11. 11.
    Vitiello B. Psychopharmacology for young children: clinical needs and research opportunities. Pediatrics. 2001;108:983–9. doi:10.1542/peds.108.4.983.PubMedCrossRefGoogle Scholar
  12. 12.
    Jensen PS, Bhatara VS, Vitiello B, Hoagwood K, Feil M, Burke LB. Psychoactive medication prescribing practices for U.S. children: gaps between research and clinical practice. J Am Acad Child Adolesc Psychiatry. 1999;38:557–65.PubMedCrossRefGoogle Scholar
  13. 13.
    Wong IC, Murray ML, Camilleri-Novak D, Stephens P. Increased prescribing trends of paediatric psychotropic medications. Arch Dis Child. 2004;89:1131–2. doi:10.1136/adc.2004.050468.PubMedCrossRefGoogle Scholar
  14. 14.
    Walley T, Mantgani A. The UK General Practice Research Database. Lancet. 1997;350:1097–9. doi:10.1016/S0140-6736(97)04248-7.PubMedCrossRefGoogle Scholar
  15. 15.
    Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998;45:419–25. doi:10.1046/j.1365-2125.1998.00701.x.PubMedCrossRefGoogle Scholar
  16. 16.
    Wood L, Coulson R. Revitalizing the General Practice Research Database: plans, challenges, and opportunities. Pharmacoepidemiol Drug Saf. 2001;10:379–83. doi:10.1002/pds.608.PubMedCrossRefGoogle Scholar
  17. 17.
    Hollowell J. The General Practice Research Database: quality of morbidity data. Popul Trends. 1997;87:36–40.PubMedGoogle Scholar
  18. 18.
    BNF 48. Joint Formulary Committee. British National Formulary. 48th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2004.Google Scholar
  19. 19.
    Armitage P, Berry G. Statistical methods in medical research. 3rd ed. Oxford, England: Blackwell Science; 1994.Google Scholar
  20. 20.
    NICE. Guidance on the Use of Methylphenidate (Ritalin, Equasym) for Attention Deficit/Hyperactivity Disorder (ADHD) in Childhood. Technology Appraisal Guidan no.13.http://www.nice.org.uk/nicemedia/pdf/TA098guidance.pdf. Accessed 6 Dec 2008.
  21. 21.
    Thapar AK, Thapar A. Attention-deficit hyperactivity disorder. Br J Gen Pract. 2003;53:225–30.PubMedGoogle Scholar
  22. 22.
    Jick H, Kaye JA, Black C. Incidence and prevalence of drug-treated attention deficit disorder among boys in the UK. Br J Gen Pract. 2004;54:345–7.PubMedGoogle Scholar
  23. 23.
    Bramble D. Annotation: the use of psychotropic medications in children: a British view. J Child Psychol Psychiatry. 2003;44:169–79. doi:10.1111/1469-7610.00111.PubMedCrossRefGoogle Scholar
  24. 24.
    Taylor E, Hemsley R. Treating hyperkinetic disorders in childhood. BMJ. 1995;310:1617–8.PubMedGoogle Scholar
  25. 25.
    Steinhausen HC, Erdin A. A comparison of ICD-9 and ICD-10 diagnoses of child and adolescent psychiatric disorders. J Child Psychol Psychiatry. 1991;32:909–20. doi:10.1111/j.1469-7610.1991.tb01918.x.PubMedCrossRefGoogle Scholar
  26. 26.
    Murray ML, de Vries CS, Wong IC. A drug utilisation study of antidepressants in children and adolescents using the General Practice Research Database. Arch Dis Child. 2004;89:1098–102. doi:10.1136/adc.2004.064956.PubMedCrossRefGoogle Scholar
  27. 27.
    Pappadopulos EA, Tate Guelzow B, Wong C, Ortega M, Jensen PS. A review of the growing evidence base for pediatric psychopharmacology. Child Adolesc Psychiatr Clin N Am. 2004;13:817–55. doi:10.1016/j.chc.2004.04.007.PubMedCrossRefGoogle Scholar
  28. 28.
    Zito JM, Safer DJ, Berg LT, Janhsen K, Fegert JM, Gardner JF, et al. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health. 2008;25(2):26.CrossRefGoogle Scholar
  29. 29.
    Safer DJ, Zito JM, DosReis S. Concomitant psychotropic medication for youths. Am J Psychiatry. 2003;160:438–49. doi:10.1176/appi.ajp.160.3.438.PubMedCrossRefGoogle Scholar
  30. 30.
    Zito JM, Safer DJ, Riddle MA, Johnson RE, Speedie SM, Fox M. Prevalence variations in psychotropic treatment of children. J Child Adolesc Psychopharmacol. 1998;8:99–105. doi:10.1089/cap.1998.8.99.PubMedCrossRefGoogle Scholar
  31. 31.
    Cox ER, Motheral BR, Henderson RR, Mager D. Geographic variation in the prevalence of stimulant medication use among children 5 to 14 years old: results from a commercially insured US sample. Pediatrics. 2003;111:237–43. doi:10.1542/peds.111.2.237.PubMedCrossRefGoogle Scholar
  32. 32.
    European Commission. Better medicines for children: proposed regulatory actions on paediatric medicinal products. Brussels, Belgium. 2002. Available from: http://ec.europa.eu/enterprise/pharmaceuticals/pharmacos/docs/doc2002/feb/cd_pediatrics_en.pdf. Accessed 6 Dec 2008.
  33. 33.
    European Medicines Agency for the Evaluation of Medicines for Human Use (EMEA). EMEA/PEG Procedure for identifying Paediatric Needs. London, UK. 2005. Available from: http://www.emea.europa.eu/pdfs/human/paediatrics/17519205en.pdf. Accessed 6 Dec 2008.

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  1. 1.Centre for Paediatric Pharmacy Research, The School of PharmacyUniversity of LondonLondonUK
  2. 2.Postgraduate Medical SchoolUniversity of SurreySurreyUK

Personalised recommendations